Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Michael Rabbia"'
Autor:
Francesco Muntoni, Barry J. Byrne, Hugh J. McMillan, Monique M. Ryan, Brenda L. Wong, Juergen Dukart, Amita Bansal, Valerie Cosson, Roxana Dreghici, Maitea Guridi, Michael Rabbia, Hannah Staunton, Giridhar S. Tirucherai, Karl Yen, Xiling Yuan, Kathryn R. Wagner, the Taldefgrobep Alfa Study Group
Publikováno v:
Neurology and Therapy, Vol 13, Iss 1, Pp 183-219 (2024)
Abstract Introduction Duchenne muscular dystrophy (DMD) is a genetic muscle disorder that manifests during early childhood and is ultimately fatal. Recently approved treatments targeting the genetic cause of DMD are limited to specific subpopulations
Externí odkaz:
https://doaj.org/article/202c472942a04da4895185c648dc27dc
Autor:
Susanne Ostrowitzki, Tobias Bittner, Kaycee M. Sink, Howard Mackey, Christina Rabe, Lawrence S. Honig, Emanuele Cassetta, Michael Woodward, Mercè Boada, Christopher H. van Dyck, Timo Grimmer, Dennis J. Selkoe, Andres Schneider, Kathleen Blondeau, Nan Hu, Angelica Quartino, David Clayton, Michael Dolton, Yifan Dang, Beth Ostaszewski, Sandra M. Sanabria-Bohórquez, Michael Rabbia, Balazs Toth, Udo Eichenlaub, Jillian Smith, Lee A. Honigberg, Rachelle S. Doody
Publikováno v:
JAMA neurology. 79(11)
ImportanceAlzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid plaques and τ tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease progression.ObjectiveTo investigate
Autor:
Luca Santarelli, Eriene A. Youssef, Jorge A. Quiroz, Christian Czech, Paulo Fontoura, Randi J Hagerman, Elizabeth Berry-Kravis, Russell Kinch, Lothar Lindemann, Michael Rabbia, Dennis Deptula, Rachel Langland, Chin Y Wong, Moritz Marcinowski, David R Hessl, Philip Drewitt, Carsten Horn, Amy John
Publikováno v:
Neuropsychopharmacology
Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has bee
Autor:
Susanne Ostrowitzki, Reina N. Fuji, Paulo Fontoura, Angelica Quartino, Michael Rabbia, Andres Schneider, Howard Mackey, Jillian Smith, Kaycee M. Sink, Francis Warren, Susan Yule, Rachelle S. Doody
Publikováno v:
Alzheimer's & Dementia. 15
Autor:
Wen Li, Scott W. Andersen, Steve Wilson, Richard Entsuah, Hong Liu-Seifert, Ying Tian, Jennifer Schumi, Xiaopeng Miao, Michael Rabbia
Publikováno v:
Therapeutic innovationregulatory science. 54(2)
Alzheimer’s disease (AD) has increasingly been recognized as a huge unmet medical need. Currently, there is no approved drug to cure, prevent, or even slow down the disease. It is imperative to develop disease-modifying treatments for AD to alter t
Autor:
Ekopimo Ibia, Michael Rabbia, Sarah Lipsius, Andrew S. Buchanan, Bruce Binkowitz, Yoko Tanaka
Publikováno v:
Therapeutic Innovation & Regulatory Science. 50:91-100
This article describes follow-up work extended from Tanaka et al (2011) in defining the region in multiregional clinical trials (MRCTs). The previous paper advocated a systematic approach to defining regions and recommended the sponsor to think throu
Autor:
Howard Mackey, Laurie Millar, Kaycee M Sink, Helen Lin, Susanne Ostrowitzki, Francis Warren, Paulo Fontoura, Jillian Smith, Susan Yule, Angelica Quartino, Rachelle Doody, Andres Schneider, Reina N. Fuji, Michael Rabbia
Publikováno v:
Alzheimer's & Dementia. 14
Autor:
Michael Rabbia, Paulo Fontoura, Angelica Quartino, Susanne Ostrowitzki, Lee Honigberg, Reina N. Fuji, Janice Smith, Robert Paul, Susan Yule, Thomas Blaettler, Jillian Smith, Veronica Asnaghi
Publikováno v:
Alzheimer's & Dementia. 12
Autor:
Bruce Binkowitz, Carmen Mak, Brent Burger, Alex Zolotovitski, Joshua Chen, Yoko Tanaka, Michael Rabbia, Ekopimo Ibia
Publikováno v:
Drug Information Journal. 45:575-585
This article describes the work of the PhRMA MRCT work stream in examining the points to consider when defining “region” and recommends a more systematic approach in defining region in MRCTs. This approach goes beyond drawing lines on a map. By a
Autor:
Michael Rabbia, Sunder Mudaliar, Cathy Chognot, Matthias Herz, Robert R. Henry, A. Michael Lincoff
Publikováno v:
The Lancet. 374:126-135
Despite previous reports of potential adverse cardiovascular effects of peroxisome proliferator-activated receptor (PPAR) agonists, the promise for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes is